Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia

被引：21
|
作者：
Tamura, Akihiro [1 ]
Ishida, Toshiaki [1 ]
Saito, Atsuro [1 ]
Yamamoto, Nobuyuki [1 ]
Yokoi, Takehito [1 ,2 ]
Uemura, Suguru [1 ,3 ]
Nino, Nanako [1 ,3 ]
Fujiwara, Takahiro [1 ]
Tahara, Teppei [1 ]
Nakamura, Sayaka [1 ]
Kozaki, Aiko [1 ]
Kishimoto, Kenji [1 ]
Hasegawa, Daiichiro [1 ]
Kosaka, Yoshiyuki [1 ]
机构：
[1] Kobe Childrens Hosp, Childrens Canc Ctr, Dept Hematol & Oncol, Kobe, Hyogo, Japan
[2] Osaka Univ Hosp, Dept Pediat, Suita, Osaka, Japan
[3] Kobe Univ Hosp, Dept Pediat, Kobe, Hyogo, Japan
来源：
PEDIATRIC BLOOD & CANCER | 2018年 / 65卷 / 10期
关键词：
acute myeloid leukemia; azacitidine; pediatric; post hematopoietic stem cell transplantation; CONVENTIONAL CARE REGIMENS; REGULATORY T-CELLS; MYELODYSPLASTIC SYNDROME; HYPOMETHYLATING AGENT; ELDERLY-PATIENTS; SALVAGE THERAPY; 5-AZA-2'-DEOXYCYTIDINE; MALIGNANCIES; DECITABINE; RELAPSE;
D O I：
10.1002/pbc.27284
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The dismal prognosis of pediatric acute myeloid leukemia (AML) relapsing after hematopoietic stem cell transplantation (HSCT) requires exploration of novel strategies to prevent relapse. Azacitidine (AZA) maintenance therapy could potentially reduce the recurrence rate post HSCT. Here, we presents the cases of three children with high-risk AML post HSCT who were treated with low-dose AZA maintenance therapy, demonstrating the feasibility of this therapy. Currently, all three are in complete remission for 13-41 months despite their high-risk characteristics. Our encouraging data warrant larger prospective studies to assess the efficacy and safety of low-dose AZA maintenance therapy post HSCT for pediatric patients with high-risk AML.
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Hypomethylating Agents and Low-Dose Venetoclax for Relapse Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
    Vigil, Carlos Enrique
    Silverman, Margarida
    Carter, Thomas
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2020, 26 (03) : S104 - S104
  • [22] Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia
    Ma, Yunju
    Qu, Changju
    Dai, Haiping
    Yin, Jia
    Li, Zheng
    Chen, Jia
    Qiu, Huiying
    Sun, Aining
    Miao, Miao
    Fu, Chengcheng
    Jin, Zhengming
    Zhu, Xiaming
    Wu, Depei
    Tang, Xiaowen
    BLOOD, 2019, 134
  • [23] Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome
    Guillaume, Thierry
    Malard, Florent
    Magro, Leonardo
    Labopin, Myriam
    Tabrizi, Reza
    Borel, Cecile
    Chevallier, Patrice
    Vigouroux, Stephane
    Peterlin, Pierre
    Garnier, Alice
    Rubio, Marie-Therese
    Huynh, Anne
    Milpied, Noel
    Moreau, Philippe
    Gaugler, Beatrice
    Yakoub-Agha, Ibrahim
    Mohty, Mohamad
    BONE MARROW TRANSPLANTATION, 2019, 54 (11) : 1815 - 1826
  • [24] Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome
    Thierry Guillaume
    Florent Malard
    Leonardo Magro
    Myriam Labopin
    Reza Tabrizi
    Cécile Borel
    Patrice Chevallier
    Stéphane Vigouroux
    Pierre Peterlin
    Alice Garnier
    Marie-Thérèse Rubio
    Anne Huynh
    Noël Milpied
    Philippe Moreau
    Béatrice Gaugler
    Ibrahim Yakoub-Agha
    Mohamad Mohty
    Bone Marrow Transplantation, 2019, 54 : 1815 - 1826
  • [25] Maintenance therapy with decitabine after allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia and high-risk myelodysplastic syndrome
    Pusic, I.
    Choi, J.
    Bernabe, N.
    Abboud, C.
    Westervelt, P.
    Vij, R.
    Cashen, A.
    Uy, G.
    Stockerl-Goldstein, K.
    Holt, M.
    DiPersio, J.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S340 - S341
  • [26] Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute
    Soiffer, Robert J.
    BLOOD ADVANCES, 2020, 4 (13) : 3205 - 3208
  • [27] Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia
    Li, Li
    Zhang, Ran
    Cao, Weijie
    Bian, Zhilei
    Qin, Yang
    Guo, Rong
    Zhang, Suping
    Peng, Yingnan
    Wan, Dingming
    Ma, Wang
    LEUKEMIA & LYMPHOMA, 2023, 64 (13) : 2113 - 2122
  • [28] Maintenance therapy with Azacitidine for patients with myeloid malignancies after allogeneic hematopoietic stem cell transplantation
    Linli Lu
    Qian Cheng
    Yuhan Yan
    Xin Chen
    Yishu Tang
    Xin Li
    Scientific Reports, 15 (1)
  • [29] Venetoclax Combined with Azacitidine or low-dose Cytarabine for Relapsed Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplant
    Smith, Katy
    Fathoala, Dina
    Anthias, Chloe
    Easdale, Sandra
    Ethell, Mark
    Potter, Mike
    Mir, Farheen
    Taussig, David
    Nicholson, Emma
    BONE MARROW TRANSPLANTATION, 2021, 56 (SUPPL 1) : 188 - 189
  • [30] Outcome and Prognostic Factors of High-Risk Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
    Zhu, Cheng-ying
    Chen, Guo-feng
    Zhou, Wei
    Hou, Cheng
    Wang, Xiao-kai
    Wang, Fei-yan
    Yang, Nan
    Wang, Li
    Fang, Shu
    Luo, Lan
    Guan, Li-xun
    Zhang, Ran
    Liu, Yu-chen
    Dou, Li-ping
    Gao, Chun-ji
    ANNALS OF TRANSPLANTATION, 2019, 24 : 328 - 340
12345